Adverse effects: Specific and serious adverse effect ‐ by 24 hours Central nervous system ‐ excessive sedation · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in adverse effects: Specific and serious adverse effects by 24 hours… compared with ANTIPSYCHOTIC ‐ OLANZAPINE (low certainty).
1 finding from 1 review
Adverse effects: Specific and serious adverse effect ‐ by 24 hours Central nervous system ‐ excessive sedation · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE may leads to lower adverse effects: Specific and serious adverse effect ‐ by 24 hours… compared with ANTIPSYCHOTIC & BENZODIAZEPINE ‐ HALOPERIDOL + MIDAZOLAM (low certainty).
1 finding from 1 review
Adverse effects: Specific and serious adverse effects by 24 hours (not death) Central nervous system ‐ seizure · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in adverse effects: Specific and serious adverse effects by 24 hours… compared with ANTIPSYCHOTIC ‐ HALOPERIDOL (low certainty).
1 finding from 1 review
Adverse effects: Specific and serious adverse effect ‐ by 24 hours Central nervous system ‐ excessive sedation · people with psychosis‐induced aggression
1 finding from 1 review
Adverse effects (e.g. thermal sensitivity, over-eruption, TMJ symptoms, poor aesthetics, reduced oral hygiene) · Adults with chronic periodontitis
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects (e.g. thermal sensitivity, over-eruption, TMJ symptoms, poor aesthetics, reduced oral hygiene) · Adults with chronic periodontitis
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: Specific and serious adverse effect ‐ by 24 hours Central nervous system ‐ excessive sedation · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in adverse effects: Specific and serious adverse effect ‐ by 24 hours… compared with ANTIPSYCHOTIC ‐ ZIPRASIDONE (low certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · patients with motion sickness
Antihistamines may leads to higher adverse effects: sedation Assessed by: adverse effect questionnaire… compared with placebo (low certainty).
1 finding from 1 review
Clinically important adverse drug‐induced movement disorder effects on the central nervous system (EPS, NMS, MC) · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Adverse events including maternal pregnancy complications, foetal complications and adverse effects of thyroxine · subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism
Thyroxine led to lower adverse events including maternal pregnancy complications, foetal… compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Any adverse effects (including constipation, nausea, vomiting, heartburn or diarrhoea, as measured by trialists) · general population older than 2 years of age (including pregnant women), in Kenya and Mexico
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event (flu‐like symptoms) · people with mycosis fungoides
IFN‐α + acitretin showed no clear difference in common adverse effects ‐ Flu‐like symptoms (Time point of… compared with IFN‐α + PUVA (low certainty).
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found